Sign Up
Stories
Atara Biotherapeutics at Health Conference
Share
AB-2100 Phase 1/2 Trial Initiated
AI-Powered Antigen Research Partnership
Advancements in Cancer Treatment and Mar...
Affini-T Therapeutics at J.P. Morgan Hea...
Anktiva Boosts Lung Cancer Treatment
Breakthrough Bladder Cancer Vaccine Appr...
Overview
API
Atara Biotherapeutics' CEO to join panel at key health conference, highlighting their focus on off-the-shelf cell therapies utilizing EBV T-cell platform.
Ask a question
How does Atara's focus on off-the-shelf cell therapies differentiate them within the immunotherapy landscape?
How might Atara's involvement in this conference impact the future of cell therapy development?
What specific breakthroughs has Atara achieved with its EBV T-cell platform in cancer and autoimmune disease treatment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage